Biomea Fusion Inc.
Biomea Fusion develops oral small molecule therapies for diabetes and obesity, including icovamenib and BMF-650.
424B5Sep 22Latest SEC filing
Sep 22Latest story
September 2026
Sign inSign inBiomea Fusion develops oral small molecule therapies for diabetes and obesity, including icovamenib and BMF-650.